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Abstract
Oncolytic adenoviruses have shown promising efficacy in clinical trials targeting prostate cancers that frequently develop
resistance to all current therapies. The replication-selective mutants AdDD and dl922–947, defective in pRb-binding, have
been demonstrated to synergise with the current standard of care, mitoxantrone and docetaxel, in prostate cancer models.
While expression of the early viral E1A gene is essential for the enhanced cell killing, the specific E1A-regions required for
the effects are unknown. Here, we demonstrate that replicating mutants deleted in small E1A-domains, binding pRb
(dl1108), p300/CBP (dl1104) and p400/TRRAP or p21 (dl1102) sensitize human prostate cancer cells (PC-3, DU145, 22Rv1) to
mitoxantrone and docetaxel. Through generation of non-replicating mutants, we demonstrate that the small E1A12S
protein is sufficient to potently sensitize all prostate cancer cells to the drugs even in the absence of viral replication and the
E1A transactivating domain, conserved region (CR) 3. Furthermore, the p300/CBP-binding domain in E1ACR1 is essential for
drug-sensitisation in the absence (AdE1A1104) but not in the presence of the E1ACR3 (dl1104) domain. AdE1A1104 also
failed to increase apoptosis and accumulation of cells in G2/M. All E1ADCR2 mutants (AdE1A1108, dl922–947) and
AdE1A1102 or dl1102 enhance cell killing to the same degree as wild type virus. In PC-3 xenografts in vivo the dl1102
mutant significantly prolongs time to tumor progression that is further enhanced in combination with docetaxel. Neither
dl1102 nor dl1104 replicates in normal human epithelial cells (NHBE). These findings suggest that additional E1A-deletions
might be included when developing more potent replication-selective oncolytic viruses, such as the AdDCR2-mutants, to
further enhance potency through synergistic cell killing in combination with current chemotherapeutics.
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Introduction
Several replication-selective oncolytic adenoviral mutants have
been developed as potential therapies for the treatment of various
cancers (virotherapy) including prostate cancer [1,2,3]. Prostate
cancer is a leading cause of cancer-related morbidity and mortality
in aging men globally with development of resistance to all
currently available therapies including anti-androgens and cyto-
toxic drugs. Therefore, therapeutics with different mechanisms of
action are urgently needed.
Virotherapy is one promising strategy to target treatment-
resistant prostate cancers and several mutants have been evaluated
in clinical trials for this malignancy [2]. The androgen receptor
(AR) is active in the majority of prostate tumors which enabled the
generation of adenoviral mutants with replication controlled by
AR response elements (AREs) to prevent replication in non-
prostate tissue [4]. In addition to altered AR-activity, prostate
cancers frequently present with genetic alterations in cell cycle and
cell death pathways including Ras/Raf/MEK/ERK, JAK/STAT
and PI3K/AKT or deregulated pRb, p16, p53, PTEN, Bcl2 and
related factors [5,6,7,8]. These alterations have also been exploited
for development of oncolytic adenoviruses since they complement
and support replication of mutants deleted in the genes regulating
the same pathways, while replication in normal tissue cannot
proceed. One example is the modified dl1520 mutant Ad5-CD/
TKrep [9,10], which has the E1B55K gene deleted with replication
complemented by non-functional p53, and mRNA-export and/or
translation in cancer cells [11,12]. Ad5-CD/TKrep also expresses
the chimeric suicide gene CD/HSV-TK and was reported to have
long-term benefits in patients with localized disease in combina-
tion with the prodrugs 5-fluorocytosine (5-FC) and ganciclovir
(GCV) or radiotherapy [13]. An optimized version, Ad5-yCD/
mutTKSR39rep-ADP is currently being evaluated in a phase II/III
randomized clinical trial in combination with chemo- and radio-
therapies (NCT00583492: www.clinicaltrials.gov) [14].
Even though clinical safety of replication-selective adenoviruses
has been demonstrated in hundreds of patients, efficacy was only
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reported in combination with other cytotoxic factors including
cisplatin, 5-fluorouracil (5-FU), gemcitabine or radiation [1,15].
Preclinical studies also demonstrate that several recently developed
E1ACR2-deleted mutants such as AdDCR2, AdDD and AdD24,
complemented by deregulated pRb/cell cycle pathways, have
significantly higher efficacy in combination with various cytotoxic
drugs in prostate cancer models [16,17,18,19,20]. Furthermore,
adenoviruses can infect and kill both proliferating and non-
proliferating tumor cells, an important consideration in the
treatment of prostate cancers that are often slow growing.
Numerous studies have convincingly demonstrated that adeno-
viruses can interact synergistically with cytotoxic drugs to enhance
cancer cell killing, but the cellular mechanisms involved in the
responses are poorly understood. Expression of the early viral E1A
proteins in the absence of other viral genes and replication is
sufficient to induce apoptosis in cancer and normal cells and
extensive data implicate a role also in chemosensitization
[21,22,23,24,25,26,27,28,29]. The E1A transcript is differentially
spliced to generate five proteins; 13S, 12S, 11S, 10S and 9S that
peak at different time-points after infection. Numerous cellular
proteins bind to E1A mainly through three conserved regions
(CR1–3) each associated with specific proteins and functions
[11,30,31,32]. The CR3 region is only present in E1A13S and is
essential for activation of viral and cellular genes. E1A-mediated
sensitization to cytotoxic drugs has been reported for the two
major E1A proteins, 12S and 13S, and does not appear to depend
on E1ACR3-mediated transcriptional activation [25,26,27,28]. It
is not clear whether E1ACR2-binding to pRb plays a role in drug-
sensitization since both increased and decreased cell killing has
been reported with DCR2 mutants [16,19,28,29,33,34]. The
E1ACR1 and E1A N-terminal domains were reported to
contribute to drug-sensitization; deletion of CR1 partially
impaired sensitisation to adriamycin and deletion of the N-
terminus prevented sensitization [28,29]. Some important func-
tions of the N-terminal and CR1 domains are binding of histone
acetyltransferases (HATs) and cell cycle regulators such as p300/
CBP, p400, PCaF, TRRAP and p21, to alter cellular transcrip-
tional activation and repression, mRNA translation and protein
stability, in favour of viral amplification [11,30,31]
In this study we screened a panel of replicating mutants with
small E1A-deletions previously demonstrated to be defective in
binding to pRb (dl1108, dl922–947), p300 and p400 (dl1101),
p300/CBP (dl1104), and p400 and p21 (dl1102) [24,31,35,36,37],
to explore whether the specific E1A gene regions that bind to these
and other cellular factors are essential for sensitization to drugs
currently used in the clinic for prostate cancer: mitoxantrone, a
topoisomerase inhibitor, and docetaxel, a microtubule-interfering
drug. Replication-defective mutants with the corresponding
deletions in the small E1A12S protein were generated to further
explore E1A-mediated effects in the absence of E1ACR3-
mediated transcriptional activation or viral replication. We
demonstrate that expression of the small E1A12S protein alone
was sufficient to sensitise prostate cancer cells to both drugs.
E1A12S-mutants with deletions in the p400/p21- (AdE1A1102) or
pRb- (AdE1A1108) binding regions were highly potent and
synergised with the drugs. In contrast, deletion of the p300/CBP-
binding site (AdE1A1104) severely attenuated efficacy and
sensitization while the corresponding replicating E1A13S mutant
(dl1104) was less severely attentuated. Neither dl1102 nor dl1104
sensitized normal prostate (PrEC) and bronchial (NHBE) epithelial
cells to the drugs, and replication was greatly attenuated. In a
prostate cancer in vivo xenograft model (PC-3), tumor progression
was significantly inhibited with dl1102, both alone and in
combination with docetaxel. Our data suggest that future
developments of oncolytic adenoviruses may include additional
deletions in the region preceding the p300/CBP binding site in the
E1ACR1 domain but not within CR1, to improve on selectivity,
decrease toxicity to normal cells and potently synergise with
chemotherapeutics to kill cancer cells only.
Results
Replicating adenoviral mutants with small deletions in
the E1A-region have higher potency than the E1B55K-
deleted dl1520 mutant in the human PC-3 and DU145
prostate cancer cell lines
Replicating mutants that are defective in binding to p300/CBP
(dl1101, dl1104), p400/p21 (dl1101, dl1102), pRb, p130 and p170
(dl922–947, dl1108), or pRb and p130 (dl1107) [35,36,37,38], were
evaluated for cytotoxicity in human prostate cancer cells (Fig. 1A).
The PC-3 cells were highly insensitive with EC50 values for Ad5
wild type virus of 104618 ppc while 22Rv1 and DU145 cells were
at least ten times more sensitive at 1.460.6 ppc and 6.961.3 ppc
respectively (Fig. 1B). Sensitivity to each mutant varied, with
significantly lower potency for viruses with deleted p300/CBP-
binding domains (dl1101 and dl1104) (p,0.01). However, all
mutants had higher potency than the attenuated dl1520 virus
deleted in the E1B55K gene, one of the most extensively clinically
evaluated oncolytic mutant (a.k.a. ONYX-015). In the 22Rv1 cells
the dl1104 mutant was slightly less efficacious than dl1520. The
murine prostate cancer cell lines TRAMPC and RM1 were
significantly less sensitive to all viruses than the human cells with
EC50 values for Ad5 at 750061900 and 27006600 ppc respec-
tively (Supporting Fig. S1). Interestingly, the dl1101 and dl1104
were also among the least potent mutants in these cells while
dl1520 was more potent in the TRAMPC cells. The virus-
insensitive PC-3 cells were also highly insensitive to the
chemotherapeutics currently used for late-stage prostate cancer,
mitoxantrone and docetaxel (p,0.001 and p,0.05 respectively)
compared to DU145 and 22Rv1 (Supporting Fig. S2A). Both
TRAMPC and RM1 were as sensitive to mitoxantrone as the
DU145 and 22Rv1 cells but less sensitive to docetaxel (Supporting
Fig. S2B). The differences in potency between mutants were not
caused by variations in viral activity since all replicating mutants
had vp/pfu ratios of 10–20 (Supporting Table S1).
The replicating E1A-deletion mutants enhance cytotoxic
drug-induced cell killing
We previously demonstrated synergistic anti-tumor efficacy for
Ad5, dl1520 and E1ACR-deleted mutants with mitoxantrone or
docetaxel in prostate cancer models [16,19,39]. To explore
whether mutants with the small E1A-deletions evaluated above
(Fig. 1A–B) could further improve on drug-induced cell killing, low
doses (EC10 and EC25) of each deletion-mutant were tested in
combination with mitoxantrone. We found that all mutants
sensitized both virus- and mitoxantrone-insensitive (PC-3) and
virus- and mitoxantrone-sensitive (22Rv1 and DU145) cells
(Fig. 1C). In the PC-3 cells, only dl1102 was significantly more
efficacious (p,0.05) than Ad5 at both doses while other mutants
sensitized the cells to similar levels as Ad5 or slightly more at one
dose (e.g. dl1108). In 22Rv1 and DU145 cells potent sensitization
was observed with all mutants to similar levels as with Ad5.
Interestingly, the murine virus-insensitive and mitoxantrone-
sensitive TRAMPC cells were sensitized with all mutants and
dl1101 significantly decreased the mitoxantrone EC50 value
compared to Ad5 (p,0.05) (Supporting Fig. S3A). The non-
replicating E1A-deleted dl312 mutant had no effect on drug-
E1A Sensitization of Cells to Chemotherapeutics
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induced cell killing in any cell line (Fig. 1C). Several mutants also
induced synergistic cell killing, determined by combination indexes
(CI) at two constant ratios (Fig. 1D). In PC-3 cells, the synergy was
significant with all mutants at one or both ratios (CI#0.9; p,0.05
compared to the theoretical additive value 0.9,CI,1.1). In
DU145 cells, significant synergy was observed with dl1102, dl1104,
dl1108, dl922–947 and dl1520 at one or two ratios (p,0.05) and in
22Rv1 cells only with the dl922–947 mutant at one condition. A
trend towards synergy was also seen in the TRAMPC cells with
significant effects with dl922–947 and dl1520 (p,0.05) (Supporting
Fig. S3B). Similar synergistic cell killing was determined in
combination with docetaxel, again with the greatest effects in PC-3
cells and the least in 22Rv1 cells (data not shown). We conclude
that the highly virus- and drug-resistant PC-3 cells were most
effectively sensitized to the combination treatments with all
mutants. The role of specific E1A-regions could not be conclu-
sively determined with this strategy since viral replication
significantly contributed to the cell killing in the human prostate
cancer cells. Furthermore, 22Rv1 and DU145 cells support
adenoviral replication more efficiently than PC-3 cells [16,19].
Expression of the E1A12S region alone causes strong
synergistic cell killing in combination with mitoxantrone
and docetaxel
To investigate whether E1A expression alone, without contri-
bution from additional viral genes and viral replication, could
sensitize prostate cancer cells to the cytotoxic drugs, an expression
plasmid was constructed encoding only the small E1A12S (DCR3)
cDNA under control of the CMV promoter (Fig. 1A). Transient
E1A12S expression resulted in sensitization to both mitoxantrone
and docetaxel compared to the corresponding GFP-expressing
control vector in PC-3, DU145 and 22Rv1 cells (Table 1).
Although, the transfection conditions caused low levels of cell
death the drug EC50 values were not significantly different in cells
Figure 1. Potent cell killing of prostate cancer cell lines by replicating E1A-deletion mutants in combination with mitoxantrone. A)
The replicating viruses used in the study had intact E1A-region (E1A13S) except for the indicated deletions. The replication-defective mutants were
based on the E1A12S construct with the same deletions as in the replicating viruses; AdE1A1102 (D26–35), AdE1A1104 (D48–60), AdE1A1108 (D124–
127), in addition to deletion of the CR3-region, responsible for viral transcriptional activity. B) EC50 values for the replicating mutants were determined
from dose-response curves and presented as averages 6 SD, n = 3. Significantly different values compared to Ad5 are indicated. C) Sensitization of
the human PC-3, 22Rv1 and DU145 cells to mitoxantrone by fixed doses of each virus at EC10 and EC25. Data presented as percentages of
mitoxantrone EC50 values in each cell line, averages 6 SD, n = 3. Statistical analysis by 1-way Anova, *p,0.05 for drug EC50 values that were
significantly lower than the corresponding Ad5 values. The dl312 (DE1A) non-replicating virus served as negative control. D) Graphic representation
of combination indexes (CI) generated from synergy studies with mitoxantrone in combination with each replicating viral mutant at two constant
ratios 0.5 and 2.5 viral particles per cell (ppc)/nM drug. Synergistic interactions are represented by CI#0.9, antagonism by CI$1.1 and additive effects
by 0.9,CI,1.1, averages 6 SEM, n = 3–5, *p,0.05 by t-test compared to the theoretical additive values.
doi:10.1371/journal.pone.0046617.g001
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transfected with the GFP plasmid compared to mock-transfected
cells (not shown). E1A-expression levels rapidly declined over time
(Supporting Fig. S4); loss of GFP expression was also observed, but
at a slower rate. Interestingly, prostate cancer cells stably
expressing E1A could not be generated, most likely because of
the potent induction of cell death by constitutive E1A expression
in these cells. To this end a recombinant Ad5 (DE1, DE3)
expressing E1A12S under control of the CMV promoter was
generated (AdE1A12S). Cells infected with the AdE1A12S virus
expressed E1A at high and reproducible levels identical to that of
Ad5 in all cell lines (data not shown). Combinations of AdE1A12S
with mitoxantrone or docetaxel at four constant ratios resulted in
strong synergistic cell killing in PC-3 and DU145 cells (Fig. 2A). In
fact, the CI values were lower in .50% of data points for
AdE1A12S (CI = 0.50–0.8) compared to the corresponding
treatments with Ad5 and as low as those of the dl1520 mutant
(Supporting Table S2). These data demonstrate that expression of
the small E1A12S protein is sufficient to cause synergistic cell
killing in combination with mitoxantrone and docetaxel.
Figure 2. Synergistic cell killing with a replication-defective virus expressing the small AdE1A12S protein, in combination with
cytotoxic drugs. A) Isobolograms generated from EC50 values for combinations of the AdE1A12S mutant with mitoxantrone (Mit) or docetaxel
(Doc) at four constant ratios (0.5. 2.5, 12.5 and 62.5 ppc/nM drug) in PC-3 and DU145 cells. The straight lines represent the theoretical values for
additive effects and points below the line synergistic cell killing, one representative study (n = 3–4). B) Characterization of replication of the
AdE1A12S, AdE1A1102, AdE1A1108 and AdE1A1104 mutants in PC-3, DU145 and 22Rv1 cells. Levels of viral replication determined by the limiting
dilution assay (TCID50) for replicating and replication-defective mutants with identical E1A-deletions except for the additional deletion of the CR3-
domain in E1A12S. Cells were infected with each mutant at 100 ppc and harvested 72 h later, averages 6SD, n$3. The non-replicating AdGFP
mutant was used as a control in all assays, *p,0.001 for the replicating compared to the corresponding replication-defective mutant (t-test). C) qPCR
analysis of cells infected as described for the replication assays and harvested 24, 48 and 72 h later. Total copy number at each time point was
normalised to the copy numbers detected 3 h after infection in 10 ng of total DNA, averages 6 SEM, n= 2–3. D) Viral replication in normal human
primary bronchial epithelial cells (NHBE) determined by TCID50 for Ad5wt, dl1102 and dl1104 mutants infected at 100 ppc, n = 3, *p,0.005.
doi:10.1371/journal.pone.0046617.g002
Table 1. EC50 values for mitoxantrone and docetaxel in
prostate cancer cells transfected with E1A12S or GFP
expressing plasmids.
EC50 Mitoxantrone (nM) EC50 Docetaxel (nM)
E1A12S GFP E1A12S GFP
PC3 510650 21206120 1564 30610
DU145 54612 150618 963 2068
22Rv1 42615 130622 0.860.5 2.060.6
Data from one representative experiment treated with mitoxantrone for 3 days
after transfection with pcDNA plasmids expressing the respective proteins,
n = 3.
doi:10.1371/journal.pone.0046617.t001
E1A Sensitization of Cells to Chemotherapeutics
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Mutants expressing the small E1A12S proteins deleted in
the p300-, p400- or pRb-binding regions are cytotoxic to
prostate cancer
Having established strong synergistic effects with the E1A12S-
expressing mutant, various E1A-deletions were incorporated,
focusing on the regions that bind to p400 (AdE1A1102), p300/
CBP (AdE1A1104) and pRb (AdE1A1108). The deletions were
selected based on the observed sensitization with the correspond-
ing replicating mutants (dl1102, dl1104, dl1108) and previous
reports indicating that these E1A-regions are involved in apoptotic
cell killing [21,23,28,29]. As expected, the mutants had signifi-
cantly lower cell killing potency than the replicating viruses with
EC50 values 10–50 times higher than Ad5 in all three cell lines
(p,0.001) (Table 2) while the E1A-deleted dl312 mutant had EC50
values .16105 ppc. AdE1A1102 and AdE1A1108 had higher
potency than other mutants in DU145 and PC-3 cells.
AdE1A1104 caused the least cell killing in all tested cell lines
similar to findings with the replicating dl1104 mutant (Table 2,
Fig. 1B). Replication of AdE1A1102, AdE1A1104 and
AdE1A1108 was either below the limit of detection (,20 pfu/
cell) or significantly reduced (p,0.001) compared to the corre-
sponding replicating mutants up to 72 h after infection (Fig. 2B).
In agreement with these data no significant increases in viral
genome amplification over time were detected (Fig. 2C). In
contrast, the corresponding replicating viruses showed time-
dependent genome amplification to similar levels as Ad5 in
DU145 and PC-3 except dl1104, that was slightly attenuated in
PC-3 and 22Rv1 cells. We previously demonstrated that the
oncolytic mutants AdDCR2 and dl922–947 deleted in the CR2-
region similar to dl1108, had only slightly attenuated replication
and genome amplification in proliferating normal primary NHBE
and PrEC cells when compared to wild type virus [16,40].
Interestingly, replication of the dl1102 and dl1104 mutants was
significantly (p,0.005) attenuated in normal NHBE cells com-
pared to Ad5 (Fig. 2D). As expected all E1A12S-expressing
mutants rapidly killed both NHBE and PrEC cells without
detectable replication (data not shown). In conclusion, in the
prostate cancer cells none of the AdE1A12S mutants replicated
and consequently cell killing was caused solely by E1A expression.
The AdE1A1104 virus does not sensitise prostate cancer
cells to cytotoxic drugs
Next, the 22Rv1, DU145 and PC-3 cells were infected with the
non-replicating viral mutants at doses that caused ,10% cell
killing alone, at 2.5, 10 and 100 ppc respectively, and treated with
increasing doses of mitoxantrone or docetaxel (Fig. 3A). In PC-3
and DU145 cells all mutants, except AdE1A1104, were as potent
as the intact AdE1A12S virus and significantly decreased the drug
EC50 values by 40–55% for mitoxantrone and 30–50% for
docetaxel. Neither AdE1A1104 nor AdGFP sensitized the cells to
any drug. In the more sensitive 22Rv1 cells the EC50 values were
significantly decreased for mitoxantrone with all mutants except
AdE1A1104 and AdGFP, but not for docetaxel. However, a trend
towards sensitisation with AdE1A12S, AdE1A1102 and
AdE1A1108 was detected at higher doses (10 ppc; not shown).
The differences in efficacy were not caused by differences in virus
integrity since the vp/pfu ratios were 19–40 for all mutants
(Supporting Table S1) with the highest activity for AdE1A1104
(19 vp/pfu). In addition, the same trends were observed at both
lower and higher doses of all mutant viruses in PC-3 and DU145
(data not shown).
E1A-induced sensitisation to mitoxantrone is dependent
on apoptotic cell death
Both mitoxantrone and docetaxel ultimately kill cancer cells
through activation of apoptotic mechanisms resulting from DNA
damage [41,42]. Expression of E1A alone in the absence of E1B or
other viral proteins has been reported to potently induce apoptosis
in various cell types (e.g. [21,25,26]). To determine if caspase-
dependent apoptosis was involved in the E1A-mediated sensitisa-
tion in prostate cancer cells, cells were infected with AdE1A12S
mutants and treated with mitoxantrone under synergistic condi-
tions with and without the addition of the pan-caspase inhibitor v-
ZAD-fmk (Fig. 3B). Mitoxantrone-induced cell killing was greatly
reduced in all cells treated with the inhibitor. In combination-
treated cells the sensitization was completely blocked by the
caspase inhibitor. Despite the lack of sensitization to mitoxantrone
with the AdE1A1104 and AdGFP mutants, cell viability increased
with the inhibitor by preventing drug-induced apoptosis (Fig. 3B).
To further investigate the molecular mechanisms leading to
caspase activation, early changes in mitochondrial membrane
depolarisation were determined by tetramethylrhodamine uptake
(TMRE). Low doses of each AdE1A12S mutant resulting in
,10% of cells with mitochondrial depolarisation up to 96 h after
infection were combined with a dose of mitoxantrone that induced
potent depolarisation in all tested cell lines (Fig. 3C). In PC-3 and
DU145 cells, AdE1A12S, AdE1A1102 and AdE1A1108 increased
the percentages of depolarised apoptotic cells in combination with
mitoxantrone by up to 30% after 96 h compared to drug alone. In
contrast, the AdE1A1104 mutant did not further increase the
mitoxantrone-induced apoptosis and had similar effects to the
control AdGFP virus (Fig. 3C). Interestingly, no combination
increased mitochondrial depolarization in 22Rv1 cells compared
to treatment with drug alone under these conditions. We conclude
that although the small E1A12S mutants promoted potent
caspase-dependent apoptotic death in all three cell lines the early
apoptotic events differed in response to the combination
treatments with mitoxantrone; the mitochondrial pathway ap-
peared to be involved in the sensitization in PC-3 and DU145 cells
but not in 22Rv1 cells. In addition, despite increased viability in all
combination treated cells infected with AdE1A1104 in the
presence of caspase inhibitor, the mitochondrial pathway
appeared not to be activated by this mutant.
AdE1A12S, AdE1A1102 and AdE1A1108 but not
AdE1A1104 promote mitoxantrone-dependent G2/M-
induction
To further investigate the differences in sensitization, we
determined the cell cycle distribution during synergistic conditions.
The viral mutants caused minor (not significant) increases in S- or
G2/M- phases in PC-3 and 22Rv1 cells (Fig. 3D). Mitoxantrone
increased the G2/M-population in all cell lines as previously
Table 2. EC50 values (ppc) for the replication-defective
AdE1A12S, AdE1A1102, AdE1A1104 and AdE1A1108 viral
mutants and wild type virus (Ad5).
Ad5 Ad12S Ad1102 Ad1104 Ad1108
PC3 102610 30726660 17106450 50906690 21006250
DU145 862 240625 148635 255650 80620
22Rv1 1.860.5 5.261.1 6.162.0 13.363.5 5.563
Data are averages 6 SD, n = 3, p,0.001 for all mutants vs Ad5 (t-test). The non-
replicating dl312 and AdGFP control viruses had EC50 values .1610
5 ppc.
doi:10.1371/journal.pone.0046617.t002
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reported for this topoisomerase II inhibitor [41]. In PC-3 cells, the
viral mutants that caused sensitization (AdE1A12S, AdE1A1102,
AdE1A1108) further increased the drug-induced G2/M-popula-
tion from 24 to 72 h in combination with mitoxantrone but not
AdE1A1104 (Fig. 3D). The same changes were observed in 22Rv1
cells with the greatest effects 48h after treatment initiation
(Fig. 3D). Cell cycle profiles with AdE1A1104 or AdGFP in
combination with mitoxantrone were similar to that of mitoxan-
trone alone in both cell lines. The increases in G2/M were greatest
in the PC-3 cells and likely reflect the more potent sensitization of
these cells. In DU145 cells, combinations of the AdE1A12S
mutants with mitoxantrone resulted in a high fraction of
aneuploidy and greatly increased subG1- and G2/M- phases
already after 24 h making the distinction between phases difficult
(data not shown). However, the increased aneuploidy and G2/M
populations were more evident with AdE1A12S, AdE1A1102 and
AdE1A1108 than with AdE1A1104. In agreement with the cell
cycle data, mitoxantrone induced cyclin A and B levels as would
be expected for cells in the G2/M-phase (Supporting Fig. S5).
While the drug-induced increases in cyclin levels were sustained
with all E1A12S mutants, no further changes could be detected in
the combination treated cells. Overall no effects on drug-induced
cell cycle alterations or apoptotic cell killing could be detected in
AdE1A1104 infected cells.
In combination with docetaxel both dl1102 and dl1104
inhibit PC-3 tumor xenograft growth and prolong time to
tumor progression in athymic mice
To explore our findings in vivo, PC-3 cells were inoculated
subcutaneously in athymic mice as previously described [16]. As
expected, the replication-defective AdE1A12S, AdE1A1102 and
AdE1A1104 mutants did not have significant anti-tumor efficacy
in this model due to the lack of viral replication and spread,
Figure 3. All replication-defective E1A12S mutants sensitise prostate cancer cells to mitoxantrone and docetaxel except the
AdE1A1104 virus. A) Drug dose responses in each cell line were evaluated after infection with AdE1A12S, AdE1A1102, AdE1A1104, and AdE1A1108
mutants with AdGFP as negative control to determine changes in drug EC50 values. All cell lines were infected at doses killing ,10% of cells alone;
PC-3 cells at 100 ppc (left panel), DU145 cells at 10 ppc (mid panel) and 22Rv1 cells at 2.5 ppc (right panel). Data represent averages 6SD, n = 4–5
independent experiments analysed by t-test comparing EC50 values for each combination to that of drug alone, expressed as percentages, *p,0.05
and up,0.01. B) EC50 values for mitoxantrone were determined with and without simultaneous infection with viral mutants at 2.5, 10 and 100 ppc for
22Rv1, DU145 and PC-3 respectively, and with (grey bar) and without (black bar) the addition of the pan-caspase inhibitor zVAD-fmk at 25 mM. EC50
values are expressed as percentages of mitoxantrone alone (Ctrl), averages 6 SD, n = 3. C) Flow cytometry of cells infected with the AdE1A12S
mutants or treated with mitoxantrone (50 nM) alone and in combination and analysed for tetramethylrhodamine uptake (TMRE) as an indicator of
mitochondrial depolarisation and apoptosis induction. AdE1A12S, AdE1A1102, AdE1A1104, AdE1A1108, and AdGFP alone (solid arrow; all cell lines)
and AdE1A12S, AdE1A1102, AdE1A1104 and AdE1A1108 in combination with mitoxantrone (dashed arrow; 22Rv1 cells). Data expressed as %
apoptotic cells; percentages of cells that showed mitochondrial depolarisation, averages 6 SD, n = 3. D) Cells infected with each mutant at 100 (PC-3)
or 2.5 ppc (22Rv), mock infected and treated with or without mitoxantrone at 50 nM. Changes in cell cycle were analysed by flow cytometry at 24, 48
and 72 h after infection and drug treatment in PC-3 cells or after 48 h for 22Rv1 cells, one representative study (n = 3), *p,0.05 comparing G2/M-
phase in combination treated vs mitoxantrone alone, up,0.05 G2/M-phase for mitoxantrone vs mock treated.
doi:10.1371/journal.pone.0046617.g003
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neither alone nor in combination with docetaxel (not shown). In
contrast to docetaxel, mitoxantrone was too toxic for evaluation in
the PC-3 in vivo model. Differently from the replication-defective
mutants, the replicating dl1102 and dl1104 potently inhibited
tumor growth in combination with docetaxel at low doses (Fig. 4A;
p,0.05 compared to each single agent). However, only dl1102
had significant efficacy (p,0.05 compared to mock treated) when
administered alone. In a second study, median time to progression
was determined to be 40, 30 and 28 days for dl1102, dl1104 and
docetaxel respectively. In contrast, more than 50% of the
combination-treated animals had still not progressed at the end
of the study, 70 days after treatment (Fig. 4B). The enhanced anti-
tumor efficacy observed in vivo was verified in cultured PC-3 cells
treated with viral mutants and docetaxel. Combination-treatments
with docetaxel caused similar synergistic effects as observed with
mitoxantrone. The most potent synergistic cell killing was achieved
when docetaxel was combined with dl1102 (p,0.05) and to a
lesser degree with dl1104 (Fig. 4C). The replication-defective
AdE1A1102 was less potent than the replicating dl1102 with
synergy in two data points (p,0.05) while AdE1A1104 did not
cause significant synergy.
The replicating dl1102 and dl1104 mutants do not
enhance cell killing in combination with cytotoxic drugs
in primary human prostate (PrEC) and bronchial (NHBE)
epithelial cells
In contrast to the cancer cell lines, no significant enhancement
of cell killing was observed in normal primary PrEC or NHBE
cells with any mutants in combination with mitoxantrone (Fig. 5A–
B) or docetaxel (not shown). In agreement with our previous
findings, Ad5 wild type virus sensitized both PrEC and NHBE
cells to the drugs while no significant sensitization was observed
with the replication-selective oncolytic AdDD mutant as previously
reported [16,40]. A trend towards increased cell killing was noted
for dl1104, but not with other mutants, in combination with higher
doses of mitoxantrone (Fig. 5C). Taken together, these findings
suggest that both dl1102 and dl1104 are safe with low toxicity to
normal tissue and have potential for future developments of
oncolytic mutants targeting prostate cancer. However, efficacy for
the dl1104 mutant administered alone was poor and significantly
less than with dl1102.
Figure 4. The dl1102 mutant prolongs time to progression in combination with docetaxel in PC-3 xenografts in vivo. A) Animals with
PC-3 subcutaneous tumor xenografts were treated with the dl1102 (filled triangle) or dl1104 (filled circle) mutants or mock treated with dl312 (filled
square) at 16109 vp (i.t. injections on day 1, 3, and 5) with and without docetaxel at 10 mg/kg (D10; i.p. administration on day 2 and 8, open squares),
and tumor growth was monitored. *p,0.05, treatments compared with mock and single-agent treatments (one-way ANOVA), p,0.05 for dl1102
alone compared to mock, n = 6. B). In a second study animals with PC-3 subcutaneous tumor xenografts were treated as above with the indicated
suboptimal doses of mutants at 16109 vp and docetaxel at 10 mg/kg (D10) or the respective combinations. Median time to tumor progression
(tumor volume .500 ml) was determined by Kaplan-Meier survival analysis (8–10 animals per group). *p,0.05, combination-treated compared with
docetaxel. C) PC-3 cells infected with the indicated mutants and treated with docetaxel at four constant ratios; 0.5, 2.5, 12.5 and 62.5 ppc/nM drug
(indicated by the wedges). CI values were calculated from isobolograms and CI#0.9 were considered synergistic, averages 6SEM, n= 3, *p,0.05 vs
the theoretical additive values (0.9,CI,1.1) represented by the dashed line.
doi:10.1371/journal.pone.0046617.g004
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Discussion
The findings presented here demonstrate potent E1A-mediated
chemosensitization in three prostate cancer cell lines, with and
without functional AR and p53 pathways. We show that
expression of the small viral E1A12S protein from a replication-
defective virus or plasmid is sufficient to synergistically enhance
cell killing in combination with mitoxantrone or docetaxel. The
contribution of specific E1A-domains in the enhancement of drug-
induced apoptosis was determined in the absence of the E1ACR3
transcriptional activation domain. We demonstrate that a region
within E1ACR1 (amino acids 48–60) is essential for drug-
sensitization, while both E1ACR2 and a region proximal to
CR1 (amino acids 26–35) are redundant in our prostate cancer
models. We also demonstrate that a panel of E1A13S-expressing,
fully replicating deletion-mutants, previously established as defec-
tive in binding to pRb, p400/TRRAP, PCAF, p21 or p300/CBP
[24,30,31,35,36,37], sensitized the cells to cytotoxic drugs to
different degrees dependent on the specific cell line. Importantly,
the replicating dl1108 and dl922–947 (DE1ACR2), and the dl1102
(amino acids 26–35 deleted) mutants consistently killed all tested
prostate cancer cells and sensitized the highly treatment-resistant
PC-3 cells to both mitoxantrone and docetaxel to a greater degree
than wild-type virus. In contrast, dl1104 and dl1101 (amino acids
26–35 and 4–24 deleted, respectively) had lower cell killing
potency and were only slightly better than the attenuated dl1520
virus. Interestingly, while the corresponding non-replicating
AdE1A12S, AdE1A1102 and AdE1A1108 also potently enhanced
mitoxantrone- and docetaxel- induced cell killing, the AdE1A1104
mutant did not sensitize any cells. Binding of cellular factors to
specific amino acid motifs in E1A have previously been elegantly
demonstrated by numerous researchers, therefore, we did not
perform additional binding assays in this study (reviewed in
[11,30]). Taken together with previous reports, our findings
indicate that binding of p300/CBP to the E1A12SCR1 domain is
the most likely factor to play a role in sensitization with
AdE1A1102, AdE1A1108 and AdE1A12S. Interestingly, when
the CR1 domain was deleted in the large E1A13S protein as in
dl1104, sensitization was observed, albeit at a lower level. A
possible reason might be the recently discovered additional
binding site for the p300/CBP complex in the E1ACR3-domain
(present in E1A13S) [32]. Binding of p300/CBP to E1A13SCR3
mainly contributes to transcriptional activation, while binding to
the E1A12SCR1 region suggests transcriptional repression
[32,43].
The cellular mechanisms involved in E1A-dependent drug-
sensitization are elusive, mostly because numerous cellular
proteins can bind to overlapping regions in E1A and have related
functions. Several histone acetyl transferases (HATs) bind to the
N-terminal and CR1 domains of E1A including p400, p300/CBP,
PCAF, TRRAP to name a few. HATs are major regulators of
cellular functions and E1A-binding to HATs interferes with
normal cell homeostasis, for example, selective transcriptional
activation/repression by E1A-binding to p400 and a more general
transcriptional repression by binding to p300/CBP. The E1A
p300/CBP complex acts as a scaffold to TFIID preventing
transcription factor binding to TATA domains [28,44]. Lack of
Figure 5. Primary human prostate (PrEC) and bronchial (NHBE) epithelial cells are not sensitive to combinations of viral mutants
and cytotoxic drugs. A–B) Normal human prostate (PrEC; A) and bronchial (NHBE; B) epithelial cells were infected with the replicating dl1102,
dl1104, Ad5wt, AdDD and the non-replicating Ad1102 and Ad1104 at 10 ppc alone (white bars) and in combination with mitoxantrone (M) at 200 nM
(crossed and striped bars). Cell viability was determined by the MTS assay 72 h later. The theoretical additive (Addit) values are indicated by grey bars,
*p,0.05 compared to expected additive cell killing, n = 2. C) PrEC cells were infected at increasing doses with the dl1102, dl1104 and the oncolytic
mutant AdDD with and without the addition of 300 nM mitoxantrone (M). Data are presented as the percentages of the viral EC50 values in
combination with mitoxantrone compared to virus alone, n = 3. Mitoxantrone alone caused 2–8% cell death and was corrected for in the calculations.
doi:10.1371/journal.pone.0046617.g005
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p300/CBP binding to E1A12S (AdE1A1104) attenuates protein
degradation and increases the levels of c-myc and E2F, while lack
of p400 binding (AdE1A1102) would result in increased protein
degradation through higher expression of HDM2 and ubiquitina-
tion [45]. Overall, binding of either p400 or p300/CBP to
E1A12S inhibits p21-mediated cell cycle arrest and promotes cell
cycling in the presence of DNA-damage ultimately resulting in
apoptotic death [11,28,30,31]. However, none of the viral mutants
significantly affected p21 levels under our conditions and did not
prevent mitoxantrone-induced increases of p21, while E1A12S
and AdE1A1102 but not AdE1A1104 promoted degradation of
the AR in 22Rv cells within 24 h (data not shown). The AR is
partly stimulated by p300 acetylation and is attenuated by histone
deacetylases (HDACs) and MDM2-mediated degradation [46].
Although, we did not explore the exact role of E1A-p300/CBP
binding in drug sensitization we speculate that cellular protein-
degradation, including growth-stimulating factors such as the AR,
is promoted by opposing cellular factors when the p300/CBP
enzyme activity is squelched by E1A and thereby contributing to
cell death.
The E1A-p300/CBP complex also represses p53-dependent
transcription, in turn preventing cell cycle arrest to support high
levels of viral replication [45,47]. A trend towards lower levels of
replication for dl1104 was noted in the p53-positive 22Rv cells.
The AdE1A1104 mutant was the only virus that did not further
increase the mitoxantrone-induced G2/M cell population or
aneuploidy. In contrast, mutants lacking the pRb- or p400-
binding domains were as effective as the intact AdE1A12S in
supporting the accumulation of cells in G2/M in both PC-3 and
22Rv1 cells. The already deregulated cell cycle in these cells is
apparently sufficient to compensate for the absence of pRb-E1A
and p400/p21-E1A complexes. E1ACR1-deleted mutants have
been reported to undergo more rapid proteasomal degradation
than wild-type E1A [48]. We noted a slightly lower level of
immunoreactive E1A expressed from the AdE1A1104 mutant and
to rule out a dose-dependent effect on sensitization we infected
cells with increasing doses. However, sensitization to drugs was still
not observed (data not shown). These results suggest that infection
with all mutants under our conditions resulted in E1A-expression
that reached the critical threshold required for cellular effects and
consequently, the attenuated potency of E1A1104 mutants is
caused by the absence of binding to p300/CBP or other cellular
factors.
Additional factors that interfere with E1A-induced chemosensi-
tization are the many genetic alterations present in cancer cell
lines. For example, binding of p300/CBP was previously reported
not to be essential for apoptosis-induction while p400-binding
enhanced the sensitization to adriamycin in primary mouse
embryo fibroblasts (MEF) [28]. Similar findings were also observed
in primary transformed retinal cells [49]. Induction of apoptosis
and sensitization was reported to be dependent on p300 or p400
stabilization of p53 through an ARF-mediated mechanism and by
induction of E2F or c-Myc [28,49]. However, our findings
presented here clearly demonstrate that E1ACR1 (p300-binding;
D48–60) was essential for enhancement of drug-induced apoptosis
but not the p400-binding region (D26–35) and E1ACR2 (pRb-
binding; D122–129) in our prostate cancer models. A major
difference between our study and previous reports is the use of
prostate cancer cell lines and the cytotoxic drugs mitoxantrone
and docetaxel, explored here for the first time with these mutants.
We speculate that the deregulated signalling pathways in prostate
cancer cells, including aberrant control of cell cycle progression
and death, compensate for many of the E1A-functions that are
required for sensitization in normal or transformed cells.
Importantly, we demonstrate that non-replicating E1A12S and
fully replicating mutants with the p300 or p400 binding domains
ablated could not sensitize normal cells, neither PrEC nor NHBE,
to the cytotoxic drugs. Furthermore, dl1102 and dl1104 replication
was significantly attenuated in the NHBE cells. Together with our
previous reports demonstrating that replicating viruses deleted in
the E1ACR2 domain (AdDD and dl922–947) do not sensitize
NHBE cells to cytotoxic drugs, these findings are important for
future engineering of oncolytic viruses without toxicity to normal
tissue [16,40]. Previously, the E1A N-terminal and CR1 domains
were reported as essential for apoptosis-induction, while the role of
E1ACR2 was not clearly determined [29,50]. In this report and in
our previous studies we showed that the E1ACR2 region is
redundant for sensitization in prostate cancer cells both in the
replication-defective AdE1A1108 and replication-selective dl922–
947 and AdDD mutants [16,19]. Recent findings suggest that CR1
and CR2 domains might cooperate in binding to cellular factors
[11,32,51], further supporting our observations that the CR1
domain is important both for viral potency and for interaction
with cellular factors.
In combination with the cytotoxic drugs all non-replicating
mutants, except AdE1A1104, induced caspase-dependent apop-
tosis in all three cell lines although, mitochondrial membrane
depolarisation was only increased in DU145 and PC-3 cells and
appeared to be dependent on the presence of the p300/CBP
binding domain. The lack of further increases in mitochondrial
depolarisation in 22Rv1 cells indicate that apoptosis is induced
through direct caspase activation in these cells for example, by
E1A-mediated caspase 8 and 3 activation through E1A-binding to
the caspase 8 inhibitor cFLIP [52]. Activation of the seemingly
different pathways in the three cell lines is likely the consequences
of specific genetic alterations in each cell line [5,8]. The most
obvious differences are the functional p53 pathway and AR
signalling in 22Rv1 cells but not in PC-3 and DU145 cells. It is
possible that the presence of p53 renders these cells more sensitive
to both E1A- and drug-induced cytotoxicity, reflected in the
significantly lower EC50 values for both sets of compounds in 22Rv
cells. Furthermore, 22Rv1 cells are more infectible than PC-3 cells
[19]. Extensive in depth studies would be required to delineate the
signalling cascades that cause the observed differences in each cell
line and with each mutant, even though overall enhancement of
cell killing is the final result in all three cell lines.
We have for the first time demonstrated that the small E1A12S
protein alone can sensitize prostate cancer cells to mitoxantrone
and docetaxel and that a mutant without the p400/p21-binding
domain (AdE1A12S1102) caused similar potent sensitization and
enhanced apoptosis. The corresponding replicating dl1102 mutant
had higher potency than wild-type virus in synergy assays with
both drugs. Interestingly, the dl1102 mutant alone, but not dl1104,
significantly reduced tumor growth in the PC-3 xenograft model in
vivo. Both dl1102 and dl1104 were highly efficacious in combina-
tion with docetaxel and significantly prolonged time to progres-
sion. Even though the deregulated cell cycle control in PC-3 cells is
sufficient to support replication of all tested mutants including the
DCR2 mutants, viral efficacy was attenuated for the dl1104 virus
when given alone. Overall, efficacy in our experimental models
was significantly higher with the replicating dl1102 mutant
compared to dl1104, both when given alone and in combination
with mitoxantrone and docetaxel. In addition, replication of this
mutant was significantly attenuated in the normal NHBE cells and
no sensitization to drugs was observed in normal cells.
To date, the choice of E1A-deletions has been defined by the
genetic complementation of deregulated cellular pathways such as
the potent AdDCR2 viruses. However, improvements in future
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therapies for prostate cancer will likely include multimodal
strategies and we suggest that to optimise efficacy, the intrinsic
sensitizing properties of E1A and deletion of small protein-binding
domains such as the p400/p21-binding region, should be
investigated in combination with the highly potent and selective
AdDCR2 mutants.
Materials and Methods
Cancer cell lines
The human prostate carcinoma cell lines PC-3 (ECACC, UK),
DU145 and 22Rv1 (ATCC, USA), the murine prostate cell lines
TRAMP-C1 (mouse transgenic Probasin-TAg prostate cancer;
ATCC) and RM1 (ras/myc-transformed; kind gift from Prof T.C.
Thompson, Baylor College of Medicine, Houston, TX [53]) were
grown in Dulbecco’s Modified Eagle Medium (D-MEM) supple-
mented with 10% foetal calf serum (FCS). All cell lines were
authenticated by STR-profiling (Cancer Research UK and LGC
Standards, UK) and verified to be identical to the profiles reported
by ATCC and the original vials at the end of the studies. The
primary normal human prostate (PrEC) and bronchial (NHBE)
epithelial cells were cultured according to the manufacturer’s
instructions (Lonza).
Adenoviruses
All replicating E1A-deletion mutants were serotype 5 (Ad5),
based on the dl309 backbone (E3B-deleted) with the following E1A
amino acid deletions: dl1101 (DE1A4–25), dl1102 (DE1A26–35),
dl1104 (DE1A48–60 in CR1), dl1107 (DE1A111–123), dl1108
(DE1A124–127 in CR2) and dl922–947 (DE1A122–129 in CR2).
The dl1101–1108 series of mutants were kind gifts from Prof. S.T.
Bayley and Prof. J.S. Mymryk [35,36,37]. The selectively
replicating dl1520 mutant (DE1B55K, DE3B), Ad5 (wild type),
non-replicating AdGFP (DE1) and dl312 (DE1A, DE3B) were used
as controls. All viruses had a viral particle to infectious unit ratio of
10–40 vp/pfu.
Cell killing assay and synergistic interactions
Dose response curves to viral mutants, mitoxantrone (Onko-
trone; Baxter) and docetaxel (Taxotere; Fluka) were generated by
serial dilutions to determine the concentrations killing 50% of cells
(EC50). Cell viability and cell killing efficacy were analysed 3–6
days after treatment using the MTS-assay (Promega). Synergistic
interactions were determined at four constant dilution ratios of
viruses and drugs at 0.5, 2.5, 12.5 and 62.5 viral particles per cell
(ppc)/nM drug and isobolograms were generated from individual
EC50 values followed by determination of combination index (CI)
as previously described [16,19,39]. Each data point was
determined from triplicate samples, and repeated 3–5 times.
Synergy was defined as a greater effect on cell death than the
theoretical additive values; CI#0.9 = synergy (S), CI$1.1 = anta-
gonism (A) and 0.9,CI,1.1 additive (Add) effect [54]. In
sensitisation studies the cells were treated with serial dilutions of
drugs and fixed doses of viral mutants at 2.5, 10 and 100 ppc in
the 22Rv1, DU145 and PC-3 cells respectively, or with serial
dilutions of virus and fixed doses of drugs at 10 or 50 nM for
mitoxantrone and 0.1 or 1.0 nM for docetaxel. Data are presented
as percentages of the EC50-values for drug or virus alone after
correction for cell death induced by the corresponding control
(virus or drug alone; ,15%). The pan-caspase inhibitor zVAD-
fmk (Calbiochem/Merck, UK) was added at 25 mM to inhibit cell
killing.
Generation of E1A-expressing vectors and replication-
defective E1A12S-mutants
Total RNA was isolated from A549 cells infected with Ad5 at
100 ppc for 24 h (Trizol Reagent; Invitrogen), cDNA was
synthesized with TaqMan Reverse Transcription Reagent and
oligo(dT) primers (Applied Biosystems), amplified with E1A
primers and cloned into a pCR2.1-TOPO vector (Invitrogen).
E1A12S inserts were verified by sequence analysis, cloned into
pShuttle-CMV vectors (Stratagene, TX, USA) and were either
used to transfect prostate cancer cells directly with the JetPEI-
RGD reagent (PolyPlus) or were further linearised and recom-
bined with a pAdEasy-1 plasmid (DE1, DE3; Stratagene) into the
E1A site according to the manufacturer’s instructions. The
AdE1A1102, AdE1A1104 and AdE1A1108 mutants were gener-
ated by gene splicing by overlapping extension PCR (SOEing
PCR) using E1A12S as the template. The PCR fragments were
cloned into a pCR2.1-TOPO vector, sequenced and further
cloned into the pShuttle-CMV vector and recombined with the
pAdEasy-1 plasmid. All recombinant viral DNA was isolated,
linearized and transfected into HEK293 cells. The resulting viral
mutants were analyzed, characterized and sequenced to verify the
specific inserts and deletions as previously described [16].
Replication assay
Human prostate cancer cells were seeded at 26105 cells/well in
6-well plates and 24 h later infected with viruses at 10–100 ppc.
Cells and media were collected at 24–72 h post-infection, freeze-
thawed and analyzed by the tissue culture inhibitory dose at 50%
(TCID50) using JH293 cells, as previously described [55]. Each
sample was determined in triplicate and data from three
independent studies were averaged and expressed as pfu/cell 6
SD.
Quantitative PCR (qPCR)
Cells were infected with viral mutants at 10–100 ppc and DNA
extracted 3, 24, 48 and 72 h after infection using the DNA blood
extraction kit (Promega). Viral genomes were quantified in 10 ng
of sample DNA with the following primers: hexon-forward; 59-
GGACAGGCCTACCCTGCTAAC-39, hexon-reverse; 59-
TGCTGTCAACTGCGGTCTTG-39. Power SYBR Green Mas-
ter Mix was added and qPCR performed (7500 Real Time PCR
System; Applied Biosystems). Results were expressed as the ratio of
viral genome copies at each time point relative to that at 3 h after
infection as previously described [16].
Reverse transcription (RT)-qPCR
The 22Rv1, DU145 and PC-3 cells were infected with viral
E1A-mutants at 2.5, 10 and 100 ppc respectively and/or treated
with mitoxantrone at 50 nM for 24 h followed by RNA extraction
(Trizol Reagent). First-strand cDNA was synthesized from 1 mg of
total RNA using MMLV-Reverse transcriptase and random
hexamer primers for E1A and 18S RNA as previously described
[56]. The qPCR was performed as described above and results
were expressed as the ratio of E1A cDNA to cellular 18S cDNA
(g/g6103) in each sample, n = 3.
Flow cytometry analysis
Cells were infected with AdE1A-mutant viruses at 10–100 ppc
and/or treated with mitoxantrone at 50 nM or docetaxel at 1 nM
and harvested 24–96 h later. For cell cycle analysis, cells were
fixed (70% ethanol, 5 mg RNase A) and analysed on a
FACSCalibur instrument (Becton Dickinson) after addition of
10 mg propidium iodine (PI). Changes in mitochondrial membrane
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potential (Dy) were determined by staining with tetramethylrho-
damine ethyl ester perchlorate (TMRE; Molecular Probes/
Invitrogen) at 60 ng/ml in PBS containing 4–6-diamidino-2-
phenylindole (DAPI) at 1 mg/ml and analyzed on an LSRI (Becton
Dickinson), previously described [56].
Immunoblot analysis
Cells were treated with viruses and drugs as described above,
harvested and lysed 24–72 h post-infection (25 mM Tris-HCl,
150 nM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM NaF, 1% NP-
40 (v/v) 1% sodium deoxycholate, 0.1% SDS containing a
protease inhibitor cocktail; Roche). Total proteins, 10–20 mg, were
separated on SDS-polyacrylamide gels under reducing conditions,
transferred to polyvinylidene fluoride membranes (PVDF; Invitro-
gen) and detected with the following antibodies: cyclins A, B and D
at 1:200 (Santa Cruz Biotechnology), rabbit anti-Ad2/5 E1A at
1:200 (SC-430), rabbit anti-hexon at 1:2000 (AutogenBioclear),
mouse anti-ß-tubulin at 1:20000 (Sigma-Aldrich) and goat anti-
actin at 1:1000 (SC-1615). Detection was by horseradish
peroxidase-conjugated secondary (Dako) antibody as appropriate
and chemiluminescence reagent (Amersham/Pharmacia) followed
by autoradiography (BioMax film; Kodak).
In vivo tumor growth
Five to six week old male C57Bl/6 athymic (ICRF nu/nu; CR
UK) mice were maintained in individually ventilated cages (IVC)
equipped with bedding and stress reducing modules. Animals had
free access to food and water at all times. Inoculation of tumor
cells and all injections were performed on anesthetized animals
using an isoflurane vaporizer delivering 2–3% isoflurane, oxygen
and nitrous oxide in air. Tumors were grown in one flank by
subcutaneous implantation of 16107 PC-3 cells as previously
described [16]. When tumors were 100620 ml animals were
randomised into treatment groups of 7–10 animals/group. Dose
responses to viral mutants and docetaxel were determined by
intratumoral administration (i.t.) of 16108–16109 vp/injection/
100 ml in PBS three times at 48 h intervals and docetaxel at
10.0 mg/kg in 100–200 ml PBS intraperitoneally (i.p.) two times
from days 2–10 after the first virus injection. Low doses of viruses
and docetaxel were selected to enable detection of additive/
synergistic effects on tumor growth inhibition. Tumor volumes
were estimated twice weekly: volume= (length6width26p)/6.
Tumor growth and progression were monitored for 3 months or
until tumors reached #1.44 cm2, at which point animals were
terminated in accordance with the UK Home Office Regulations
using isoflurane. Differences in tumor growth between treatment
groups were analysed by one-way Anova and p-values ,0.05 were
considered significant. Time to progression (tumor volume
$500 ml) was determined according to the Kaplan-Meier method
(log rank test for statistical significance).
Ethics statement
All animal studies were carried out in strict accordance with the
UK Home Office Guidelines for Animals (Scientific Procedures)
and the UKCCCR Guidelines for the Welfare of Animals in
Experimental Neoplasia. All protocols were approved by the
Committee on the Ethics of Animal Experiments of Queen Marys
University London under the Home Office project license PPL
70/6393.
Supporting Information
Figure S1 Cell killing efficacy of replication-selective
E1A-deletion mutants in the murine prostate cancer cell
lines, TRAMP-C1 and RM1. Viral EC50 values were
determined from dose-response assays and presented as averages
6 SD, n= 3. Significantly (1-way Anova) different values
compared to Ad5 are indicated; (*) p,0.05 and (**) p,0.01.
The dashed line represent the corresponding value for Ad5 in the
least sensitive human prostate cancer cell line PC-3.
(TIFF)
Figure S2 The PC-3 cells are insensitive to mitoxan-
trone and docetaxel. A) Sensitivity to the cytotoxic drugs
mitoxantrone and docetaxel in the human prostate cancer cell
lines DU145, PC-3 and 22Rv1. B) Sensitivity to mitoxantrone and
docetaxel in the murine prostate cancer cells TRAMPC and RM1.
The dotted lines represent the corresponding EC50 values for the
drug insensitive and sensitive PC-3 and 22Rv1 cells respectively.
A–B) Data presented as EC50 values (6 days after addition) in each
cell line, averages 6 SD, n= 3.
(TIFF)
Figure S3 Potent cell killing of the murine prostate
cancer cells TRAMPC infected with replicating E1A-
deletion mutants in combination with mitoxantrone. A)
Sensitization of the TRAMPC cells to mitoxantrone by fixed doses
of each virus at EC10 and EC25. Data presented as percentages of
mitoxantrone EC50 values in each cell line, averages 6 SD, n= 3.
Statistical analysis by 1-way Anova, *p,0.05 for drug EC50 values
that were significantly lower than the corresponding Ad5 values.
The dl312 (DE1A) non-replicating virus served as negative control.
B) Graphic representation of combination indexes (CI) generated
from synergy studies with mitoxantrone in combination with each
replicating viral mutant at two constant ratios 0.5 and 2.5 viral
particles per cell (ppc)/nM drug. Synergistic interactions are
represented by CI#0.9, antagonism by CI$1.1 and additive
effects by 0.9,CI,1.1, averages 6 SEM, n= 3–5, *p,0.05 by t-
test compared to the theoretical additive values.
(TIFF)
Figure S4 E1A-levels decrease over time after transfec-
tion with the E1A12S expressing plasmid. Expression levels
of E1A in 22Rv1 cells transfected with pcDNA-12S, cells were
harvested 24 h–6 d after transfection and E1A identified by
immunoblotting. Ad5 infected cells were used as a control for E1A
expression that was maximal after 48 h. One representative
experiment (n = 3).
(TIFF)
Figure S5 Mitoxantrone-induced G2/M phase is paral-
leled by increases in cyclins A and B in PC-3 cells.
Immunoblot illustrating changes in expression levels of cyclin A, B
and D in cells infected with 100 ppc of each mutant and treated
with 50 nM Mitoxantrone for 48 h. Total protein 20 mg/lane was
loaded and blotted with the respective antibody as described in
Material and Methods. No significant differences were detected
between the mutants. Representative blot (n = 4).
(TIFF)
Table S1 Ratio of viral particle (vp) to replicating virus
(pfu).
(DOC)
Table S2 Combination index (CI) for Ad5, AdE1A-12S or
dl1520 in combination with mitoxantrone or docetaxel in
the human prostate cancer cells PC3 and DU145.
(DOC)
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